Publications by authors named "Malene Olesen"
Article Synopsis
- The study investigated the impact of OPG-RANKL-TRAIL system on the growth and calcification of human vascular smooth muscle cells (HVSMCs).
- Small interfering RNA was used to reduce OPG levels, but treatments with RANKL or TRAIL did not change HVSMC proliferation or the expression of calcification-related genes.
- Overall, the findings suggest that knocking down OPG and applying RANKL or insulin does not influence the calcification process in HVSMCs, with significant variability in response among different human donors.
Background: Generalized arterial alterations, such as endothelial dysfunction, medial matrix accumulations, and calcifications are associated with type 2 diabetes (T2D). These changes may render the vessel wall more susceptible to injury; however, the molecular characteristics of such diffuse pre-atherosclerotic changes in diabetes are only superficially known.
Methods: To identify the molecular alterations of the generalized arterial disease in T2D, DNA microarrays were applied to examine gene expression changes in normal-appearing, non-atherosclerotic arterial tissue from 10 diabetic and 11 age-matched non-diabetic men scheduled for a coronary by-pass operation.
Cardiovascular disease is the leading cause of death in patients with type 2 diabetes mellitus (T2DM). We suggested that plasma osteoprotegerin (OPG), a strong, independent predictor of cardiovascular disease, could discriminate between anti-diabetic treatments depending on their benefits regarding cardiovascular disease. The South Danish Diabetes Study, an investigator-driven, randomized, controlled clinical trial lasting 2 years, was used to test this hypothesis in patient groups with different medication strategies (insulin aspart or NPH insulin, added either metformin/placebo or rosiglitazone/placebo).
View Article and Find Full Text PDF